Please wait
Exhibit 99 (a)(5)(I)

 Strictly Confidential. Not for Distribution.  Project Feather  Preliminary Discussion Materials for the Special Committee of the Board of Directors  January 28, 2026 
 
 CY 2025 and CY 2026E revenue estimates directionally in-line with financial projections  CY 2025 results in-line with ~$29.8 million revenue forecast based on preliminary internal estimates1  CY 2026E outlook directionally in-line with financial projections  Four pipeline prospects that accounted for ~$1.7 million of probability-weighted revenue in CY 2026E currently remain in the pipeline – potential for topline leakage in CY 2026E resulting from timing impacts  One new material customer in pipeline since prior discussion  Topline pressure in Kiwi business  New contract signed up with data vendor  Annual costs are slightly higher than the figures included in the financial projections, but Company management indicated potential for opportunity to offset through rationalization of existing cost structure reflected in financial projections  Company management is continuing to assess data needs going forward  Contract renegotiations remain ongoing with certain vendors and customers  CY 2025 year-end cash balance of ~$31.6 million was ~$4.7 million higher than projected  Difference primarily timing-driven due to working capital related items, including (i) unforecasted deferred revenues (i.e., cash collected in Q4 CY 2025 relating to revenues that will be accrued during CY 2026E) and (ii) certain unpaid vendor contracts, offset slightly by (iii) certain uncollected customer revenues  Company management is preparing a detailed working capital / cash roll-forward schedule, which is expected to be completed by 1/30/26  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  2  Selected Business Updates  1. Per Company management, CY 2025 audited financials are in progress but likely will not be finalized until March 2026. CY refers to Calendar Year; E refers to Estimated; H refers to Half.  Sources: Company management and Feather Financial Projections. 
 
 Preliminary Selected Companies Observations  Note: No company used in this analysis for comparative purposes is identical to the Company.  Enterprise Value equals equity market value + debt outstanding + preferred stock + minority interests – cash and cash equivalents.  Based on closing prices as of 1/26/26.  Based on market prices as of 1/26/26. Inclusive of intraday prices. Per Capital IQ.  Based on diluted shares.  Multiples based on forward looking financial information have been calendarized to the Company’s fiscal year end of December 31st.  Veradigm Inc., a company formerly known as Allscripts Healthcare Solutions, Inc. whose shares of common stock are traded over-the-counter on the OTC Pink Sheets Expert Market, is delinquent in its regulatory filings as of 1/26/26, having most recently released its full-year CY 2022 financial statements on 3/18/25, with complete annual CY 2023 and CY 2024 filings outstanding as of 1/26/26. Financial information reflects public filings including unaudited Q2 CY 2025 business update dated 9/30/25 and unaudited CY 2023 / CY 2024 business update dated 3/18/25. Forward multiples are based on estimates provided by four analysts who cover the company who provide such estimates.  LTM revenue reflects the midpoint of the estimated range of historical financial results, per public filings.  Based on public filings, analyst estimates, market data and other public information as of applicable date.  LTM revenue reflects pro forma financials for the acquisition of Kiwi, per public filings.  Reflects the last trading day prior to announcement of the Initial Canary Proposal.  CY refers to Calendar Year; E refers to Estimated; LTM refers to the most recently completed 12-month period for which financial information has been made public; Q refers to Quarter. Sources: Bloomberg, Capital IQ and public filings.  (dollars in millions, except per share values)  Selected Market Trading  Information  Selected Multiple Information  % of  % Above  Share  52-Week  52-Week  Equity Market  Enterprise   Enterprise Value [1] to Revenue [5]    Selected Companies Price [2] High [3] Low [3] Value [2] [4] Value [2] [4] LTM CY 2025E CY 2026E   Certara, Inc.  $10.11  64.4%  26.0%  $1,664.7  $1,788.2  4.30x  4.27x  4.02x  Definitive Healthcare Corp.  $2.44  43.0%  13.5%  $382.8  $470.1  1.94x  1.96x  2.01x  Health Catalyst, Inc.  $2.21  37.3%  9.7%  $173.3  $243.0  0.77x  0.78x  0.80x  Indegene Limited  $5.17  71.3%  0.7%  $1,261.2  $1,123.0  3.39x  3.14x  2.63x  OptimizeRx Corporation  $11.64  52.3%  191.6%  $225.1  $234.3  2.14x  2.17x  1.93x  Simulations Plus, Inc.  $20.11  53.4%  62.3%  $405.1  $369.5  4.70x  4.64x  4.50x  Veradigm Inc. [6] [7]  $4.90  54.4%  63.3%  $585.6  $540.6  0.93x  0.90x  0.92x  Low  37.3%  0.7%  0.77x  0.78x  0.80x  Median  53.4%  26.0%  2.14x  2.17x  2.01x  Mean  53.7%  52.4%  2.59x  2.55x  2.40x  High  71.3%  191.6%  4.70x  4.64x  4.50x  Feather - Current Price (as of 1/26/26) [8] [9]  $2.13  52.9%  29.9%  $69.6  $41.4  1.45x  1.38x  1.29x  Feather - Unaffected Price (as of 8/22/25) [8] [9] [10]  $1.77  43.9%  7.9%  $56.9  $28.1  1.05x  0.96x  0.87x  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  3 
 
 Certara, Inc.  3.70x  3.67x  3.44x  4.30x  4.27x  4.02x  0.61x  0.60x  0.57x  Definitive Healthcare Corp.  1.86x  1.88x  1.91x  1.94x  1.96x  2.01x  0.08x  0.08x  0.09x  Health Catalyst, Inc.  0.83x  0.85x  0.87x  0.77x  0.78x  0.80x  (0.06x)  (0.06x)  (0.07x)  Indegene Limited  3.81x  3.59x  3.06x  3.39x  3.14x  2.63x  (0.42x)  (0.45x)  (0.43x)  OptimizeRx Corporation  2.44x  2.47x  2.20x  2.14x  2.17x  1.93x  (0.30x)  (0.31x)  (0.27x)  Simulations Plus, Inc.  4.47x  4.45x  4.30x  4.70x  4.64x  4.50x  0.23x  0.19x  0.20x  Veradigm Inc. [4] [5]  0.94x  0.91x  0.93x  0.93x  0.90x  0.92x  (0.01x)  (0.01x)  (0.01x)  Low  0.83x  0.85x  0.87x  0.77x  0.78x  0.80x  (0.06x)  (0.06x)  (0.07x)  Median  2.44x  2.47x  2.20x  2.14x  2.17x  2.01x  (0.30x)  (0.31x)  (0.20x)  Mean  2.58x  2.54x  2.39x  2.59x  2.55x  2.40x  0.02x  0.01x  0.01x  High  4.47x  4.45x  4.30x  4.70x  4.64x  4.50x  0.23x  0.19x  0.20x  Feather - Current Price [6] [7]  1.45x  1.38x  1.29x  1.45x  1.38x  1.29x  0.00x  0.00x  0.00x  Included in Prior Materials  (12/18/25)  Included in  Current Materials (1/28/26)  Market Data as of 12/12/25  Market Data as of 1/26/26   Enterprise Value [2] to Revenue [3] Enterprise Value [2] to Revenue [3] Enterprise Value [2] to Revenue [3]    Selected Companies LTM CY 2025E CY 2026E LTM CY 2025E CY 2026E LTM CY 2025E CY 2026E   Change vs. Prior Materials [1]  Summary of Selected Companies Multiples Changes vs. Prior Materials  7. LTM revenue reflects pro forma financials for the acquisition of Kiwi, per public filings.  CY refers to Calendar Year; E refers to Estimated; LTM refers to the most recently completed 12-month period for which financial information has been made public; Q refers to Quarter. Sources: Bloomberg, Capital IQ and public filings.  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  4  Note: No company used in this analysis for comparative purposes is identical to the Company.  Computed as current materials – prior materials.  Enterprise Value equals equity market value + debt outstanding + preferred stock + minority interests – cash and cash equivalents.  Multiples based on forward-looking financial information may have been calendarized to the Company’s fiscal year end of December 31st.  Veradigm Inc., a company formerly known as Allscripts Healthcare Solutions, Inc. whose shares of common stock are traded over-the-counter on the OTC Pink Sheets Expert Market, is delinquent in its regulatory filings as of 1/26/26, having most recently released its full-year CY 2022 financial statements on 3/18/25, with complete annual CY 2023 and CY 2024 filings outstanding as of 1/26/26. Financial information reflects public filings including unaudited Q2 CY 2025 business update dated 9/30/25 and unaudited CY 2023 / CY 2024 business update dated 3/18/25. Forward multiples are based on estimates provided by four analysts who cover the company who provide such estimates as of applicable date.  LTM revenue reflects the midpoint of the estimated range of historical financial results, per public filings.  Based on public filings, analyst estimates, market data and other public information as of applicable date.  (dollars in millions, except per share values) 
 
 (100.0%)  (80.0%)  80.0%  60.0%  40.0%  20.0%  0.0%  (20.0%)  (40.0%)  (60.0%)  100.0%  Mar-21  Aug-21  Jan-22  Jan-26  Feather  Jun-22 Dec-22 May-23 Oct-23  Selected Companies Index²  Apr-24 Sep-24 Feb-25 Jul-25  Nasdaq Composite Index - Total Return  On 8/25/25, the Company announced that it received a non-binding proposal from Canary to acquire all unowned shares of Company common stock for $2.10 per share (the “Initial Canary Proposal”).  Selected Companies Index is comprised of Certara, Inc., Definitive Healthcare Corp., Health Catalyst, Inc., Indegene Limited, OptimizeRx Corporation, Simulations Plus, Inc. and Veradigm Inc. Total shareholder return information shown above reflects average return for the selected healthcare technology companies that were public over the entirety of the applicable time period.  Reflects total stockholder return since 8/22/25 (the “Unaffected Date”). Source: Capital IQ as of 1/26/26.  Selected Relative Total Stockholder Return Performance Information  Lookback Since Reverse Merger (3/3/21)  Indexed Total Stockholder Returns  Feather vs. Selected Companies Index & Nasdaq Composite Index (Lookback Since Reverse Merger)   Unaffected as of 8/22/25¹   10.0%  (13.6%)  20.3%  Since Initial Canary Proposal3  Since 3/3/21 Return  (3/3/21 - 8/22/25)  Three-Year Return  (8/22/22 - 8/22/25)  Two-Year Return  (8/22/23 - 8/22/25)  One-Year Return  (8/22/24 - 8/22/25)  (87.9%)  (58.3%)  (29.2%)  (25.6%)  (74.5%)  (52.5%)  (28.2%)  (10.3%)  71.1%  77.7%  61.5%  22.8%  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  5  Feather  Selected Companies Index²  Nasdaq Composite Index - Total Return   Current as of 1/26/26   Feather  Selected Companies Index²  Three-Year Return  (1/26/23 - 1/26/26)  Two-Year Return  (1/26/24 - 1/26/26)  One-Year Return  (1/26/25 - 1/26/26)  (32.2%)  (20.4%)  (2.3%)  (61.1%)  (51.0%)  (16.1%) 
 
 39.6%  60.3%  0.0%  0.0%  0.0%  0.0%  0.0%  <$2.10 $2.10-  $2.15- $2.17- $2.20-  $2.25-  >$2.30  <$2.10  $2.10-  $2.15- $2.17- $2.20- $2.25-  >$2.30  <$2.10 $2.10- $2.15- $2.17- $2.20- $2.25-  >$2.30  $2.15  $2.17 $2.20 $2.25  $2.30  $2.15  $2.17 $2.20 $2.25 $2.30  $2.15 $2.17 $2.20 $2.25 $2.30  33.0%  58.1%  4.4%  3.9%  0.6%  0.0%  0.0%  21.2%  41.2%  8.7%  13.6%  6.0%  3.7%  5.6%  Latest Canary Illustrative Indication2: $2.17  7.0  6.0  5.0  4.0  3.0  2.0  1.0  0.0  $1.75  $2.00  $2.25  $2.50  $2.75  8/25/25  9/8/25  9/22/25  11/17/25  1/12/26  1/26/26  10/6/25 10/20/25 11/3/25  Daily Trading Volume Feather  Last Two Months4  (11/26/25 to 1/26/26)  12/1/25 12/15/25 12/29/25  Latest Canary Illustrative Indication²  Last Month4  (12/26/25 to 1/26/26)  Historical Closing Per Share Common Stock Price & Daily Trading Volume Since Initial Canary Proposal1 (8/25/25 to 1/26/26)  Closing Stock Price ($) VWAP Since Initial Canary Proposal1 Daily Volume (millions)  Latest Canary Illustrative Indication2  On 8/25/25, the Company announced that it received a non-binding proposal from Canary to acquire all unowned shares of Company common stock for $2.10 per share.  Reflects verbally communicated revised indicative proposal of $2.17 per share received on 1/25/26 (the “Latest Canary Illustrative Indication” and, together with the Initial Canary Proposal, the “Canary Proposals”).  VWAP based on cumulative trading activity over designated period, per Bloomberg.  The figures in the above charts are based on intraday trading activity in fifteen-minute increments over the designated period, per Bloomberg. VWAP refers to Volume Weighted Average Price.  Sources: Bloomberg and Capital IQ as of 1/26/26 and Canary Proposals.  Selected Trading & VWAP Information  Since Initial Canary Proposal1  Last Three Months4  (10/26/25 to 1/26/26)  ~6.6 million shares of Feather common stock traded on 10/13/25, per Bloomberg  VWAP Volume: 1.7 million VWAP3: $2.15  Intraday High: $2.43 Intraday Low: $2.03  VWAP Volume: 1.0 million VWAP3: $2.11  Intraday High: $2.23 Intraday Low: $2.03  VWAP Volume: 0.5 million VWAP3: $2.10  Intraday High: $2.16 Intraday Low: $2.05  Latest Canary Illustrative Indication2  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  6  Latest Canary Illustrative Indication2  VWAP Volume: 9.2 million VWAP3: $2.40  Intraday High: $2.71 Intraday Low: $1.88  VWAP Volume: 4.0 million VWAP3: $2.19  VWAP Excluding 10/13/25 
 
 This presentation, and any supplemental information (written or oral) or other documents provided in connection therewith (collectively, the “materials”), are provided solely for the information of the Special Committee (the “Committee” or the “Special Committee”) of the Board of Directors (the “Board”) of Feather (the “Company”) by Houlihan Lokey in connection with the Committee’s consideration of a potential transaction (the “Transaction”) involving the Company. This presentation is incomplete without reference to, and should be considered in conjunction with, any supplemental information provided by and discussions with Houlihan Lokey in connection therewith. Any defined terms used herein shall have the meanings set forth herein, even if such defined terms have been given different meanings elsewhere in the materials. Houlihan Lokey makes no representation to any party that the information and analysis contained in the materials supports any particular determination regarding the Transaction.  The materials are for discussion purposes only. Houlihan Lokey expressly disclaims any and all liability, whether direct or indirect, in contract or tort or otherwise, to any person in connection with the materials. The materials were prepared for specific persons familiar with the business and affairs of the Company for use in a specific context and were not prepared with a view to public disclosure or to conform with any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and none of the Committee, the Company or Houlihan Lokey takes any responsibility for the use of the materials by persons other than the Committee. The materials are provided on a confidential basis solely for the information of the Committee and may not be disclosed, summarized, reproduced, disseminated or quoted or otherwise referred to, in whole or in part, without Houlihan Lokey’s express prior written consent.  Notwithstanding any other provision herein, the Company (and each employee, representative or other agent of the Company) may disclose to any and all persons without limitation of any kind, the tax treatment and tax structure of any transaction and all materials of any kind (including opinions or other tax analyses, if any) that are provided to the Company relating to such tax treatment and structure. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. income or franchise tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. income or franchise tax treatment of the transaction. If the Company plans to disclose information pursuant to the first sentence of this paragraph, the Company shall inform those to whom it discloses any such information that they may not rely upon such information for any purpose without Houlihan Lokey’s prior written consent. Houlihan Lokey is not an expert on, and nothing contained in the materials should be construed as advice with regard to, legal, accounting, regulatory, insurance, tax or other specialist matters. Houlihan Lokey’s role in reviewing any information was limited solely to performing such a review as it deemed necessary to support its own advice and analysis and was not on behalf of the Committee.  The materials necessarily are based on financial, economic, market and other conditions as in effect on, and the information available to Houlihan Lokey as of, the date of the materials. Although subsequent developments may affect the contents of the materials, Houlihan Lokey has not undertaken, and is under no obligation, to update, revise or reaffirm the materials. The materials are not intended to provide the sole basis for evaluation of the Transaction and do not purport to contain all information that may be required. The materials do not address the underlying business decision of the Company or any other party to proceed with or effect the Transaction. The materials do not constitute any opinion, nor do the materials constitute a recommendation to the Board, the Committee, the Company, any security holder of the Company or any other party as to how to vote or act with respect to any matter relating to the Transaction or otherwise or whether to buy or sell any assets or securities of any company. Houlihan Lokey’s only opinion is the opinion, if any, that is actually delivered to the Committee. In preparing the materials Houlihan Lokey has acted as an independent contractor and nothing in the materials is intended to create or shall be construed as creating a fiduciary or other relationship between Houlihan Lokey and any party. The materials may not reflect information known to other professionals in other business areas of Houlihan Lokey and its affiliates.  The preparation of the materials was a complex process involving quantitative and qualitative judgments and determinations with respect to the financial, comparative and other analytic methods employed and the adaption and application of these methods to the unique facts and circumstances presented and, therefore, is not readily susceptible to partial analysis or summary description. Furthermore, Houlihan Lokey did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Each analytical technique has inherent strengths and weaknesses, and the nature of the available information may further affect the value of particular techniques. Accordingly, the analyses contained in the materials must be considered as a whole. Selecting portions of the analyses, analytic methods and factors without considering all analyses and factors could create a misleading or incomplete view. The materials reflect judgments and assumptions with regard to industry performance, general business, economic, regulatory, market and financial conditions and other matters, many of which are beyond the control of the participants in the Transaction. Any estimates of value contained in the materials are not necessarily indicative of actual value or predictive of future results or values, which may be significantly more or less favorable. Any analyses relating to the value of assets, businesses or securities do not purport to be appraisals or to reflect the prices at which any assets, businesses or securities may actually be sold. The materials do not constitute a valuation opinion or credit rating. The materials do not address the consideration to be paid or received in, the terms of any arrangements, understandings, agreements or documents related to, or the form, structure or any other portion or aspect of, the Transaction or otherwise. Furthermore, the materials do not address the fairness of any portion or aspect of the Transaction to any party. In preparing the materials, Houlihan Lokey has not conducted any physical inspection or independent appraisal or evaluation of any of the assets, properties or liabilities (contingent or otherwise) of the Company or any other party and has no obligation to evaluate the solvency of the Company or any other party under any law.  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  6  Disclaimer 
 
 All budgets, projections, estimates, financial analyses, reports and other information (including, without limitation, estimates of potential cost savings and synergies) reflected in the materials have been prepared by management of the relevant party or are derived from such budgets, projections, estimates, financial analyses, reports and other information or from other sources, which involve numerous and significant subjective determinations made by management of the relevant party and/or which such management has reviewed and found reasonable. The budgets, projections and estimates (including, without limitation, estimates of potential cost savings and synergies) contained in the materials may or may not be achieved and differences between projected results and those actually achieved may be material. Houlihan Lokey has relied upon representations made by management of the Company that such budgets, projections and estimates have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of such management (or, with respect to information obtained from public sources, represent reasonable estimates), and Houlihan Lokey expresses no opinion with respect to such budgets, projections or estimates or the assumptions on which they are based. The scope of the financial analysis contained herein is based on discussions with the Company (including, without limitation, regarding the methodologies to be utilized), and Houlihan Lokey does not make any representation, express or implied, as to the sufficiency or adequacy of such financial analysis or the scope thereof for any particular purpose.  Houlihan Lokey has assumed and relied upon the accuracy and completeness of the financial and other information provided to, discussed with or reviewed by it without (and without assuming responsibility for) independent verification of such information, makes no representation or warranty (express or implied) in respect of the accuracy or completeness of such information and has further relied upon the assurances of the Company that it is not aware of any facts or circumstances that would make such information inaccurate or misleading. In addition, Houlihan Lokey has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows or prospects of the Company since the respective dates of the most recent financial statements and other information, financial or otherwise, provided to, discussed with or reviewed by Houlihan Lokey that would be material to its analyses, and that the final forms of any draft documents reviewed by Houlihan Lokey will not differ in any material respect from such draft documents.  The materials are not an offer to sell or a solicitation of an indication of interest to purchase any security, option, commodity, future, loan or currency. The materials do not constitute a commitment by Houlihan Lokey or any of its affiliates to underwrite, subscribe for or place any securities, to extend or arrange credit, or to provide any other services. In the ordinary course of business, certain of Houlihan Lokey’s affiliates and employees, as well as investment funds in which they may have financial interests or with which they may co-invest, may acquire, hold or sell, long or short positions, or trade or otherwise effect transactions, in debt, equity, and other securities and financial instruments (including loans and other obligations) of, or investments in, the Company, any Transaction counterparty, any other Transaction participant, any other financially interested party with respect to any transaction, other entities or parties that are mentioned in the materials, or any of the foregoing entities’ or parties’ respective affiliates, subsidiaries, investment funds, portfolio companies and representatives (collectively, the “Interested Parties”), or any currency or commodity that may be involved in the Transaction. Houlihan Lokey provides mergers and acquisitions, restructuring and other advisory and consulting services to clients, which may have in the past included, or may currently or in the future include, one or more Interested Parties, for which services Houlihan Lokey has received, and may receive, compensation. Although Houlihan Lokey in the course of such activities and relationships or otherwise may have acquired, or may in the future acquire, information about one or more Interested Parties or the Transaction, or that otherwise may be of interest to the Board, the Committee, or the Company, Houlihan Lokey shall have no obligation to, and may not be contractually permitted to, disclose such information, or the fact that Houlihan Lokey is in possession of such information, to the Board, the Committee, or the Company or to use such information on behalf of the Board, the Committee, or the Company. Houlihan Lokey’s personnel may make statements or provide advice that is contrary to information contained in the materials.  CONFIDENTIAL – PRELIMINARY – SUBJECT TO FURTHER REVIEW  6  Disclaimer (cont.) 
 
 CORPORATE FINANCE FINANCIAL RESTRUCTURING  FINANCIAL AND VALUATION ADVISORY  HL.com